<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336527</url>
  </required_header>
  <id_info>
    <org_study_id>LPEK-0096</org_study_id>
    <nct_id>NCT04336527</nct_id>
  </id_info>
  <brief_title>HoPe: Home Treatment and Peer Support for Acute Mental Health Crisis</brief_title>
  <acronym>HoPe</acronym>
  <official_title>HoPe: Home Delivered Peer Led Treatment vs Home Delivered Treatment - a Randomized Controlled Multicentre Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Ulm</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Home treatment (HT) is an effective treatment modality for patients with severe mental
      illness (SMI) in acute crisis that can often be considered equivalent to inpatient treatment
      in terms of treatment outcome. In Peer Support (PS) patients are supported by people with
      personal experiences in psychiatric crises. The current study investigates a combination of
      both approaches - a HT plus PS intervention - versus sole HT at different study sites
      throughout Germany. It is hypothesized that a peer-supported home-delivered treatment (HT
      plus PS) is more effective than a professional-led home-delivered treatment (HT alone) with
      respect to the time until hospital readmission, self-efficacy, psychosocial health, recovery
      orientation, internalized stigma and service satisfaction. Furthermore, it is hypothesized,
      that a peer-supported home delivered treatment (HT plus PS) is as effective as a
      professional-led home-delivered treatment (HT alone) with respect to disease severity and
      general functioning (secondary outcomes).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first readmission to inpatient hospital treatment</measure>
    <time_frame>1 year after last patient in</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change from baseline in self-efficacy expectation scores as assessed by SWE at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>SWE = Skala zur Allgemeinen Selbstwirksamkeitserwartung by Schwarzer &amp; Jerusalem (1999); minimum value = 10; maximum value = 40; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in self-efficacy expectation scores as assessed by SWE at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>SWE = Skala zur Allgemeinen Selbstwirksamkeitserwartung by Schwarzer &amp; Jerusalem (1999); minimum value = 10; maximum value = 40; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in self-efficacy expectation scores as assessed by SWE at twelve months</measure>
    <time_frame>twelve months after allocation</time_frame>
    <description>SWE = Skala zur Allgemeinen Selbstwirksamkeitserwartung by Schwarzer &amp; Jerusalem (1999); minimum value = 10; maximum value = 40; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in psychosocial health scores as assessed by Health-49 at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>Health-49 = Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis by Rabung et al. (2009); subscales: somatoform complaints (SOM; min-max values=0-28; higher scores mean aworse outcome); depressiveness (DEP; min-max=0-24, higher values mean a worse outcome); phobic anxiety (PHO; min-max=0-20; higher values mean a worse outcome); psychological and somatoform complaints (PSB; min-max=0-72; higher values mean a worse outcome); psychological wellbeing (WOHL; min-max=0-20; higher values mean a better outcome); interactional problems (INT; min-max=0-28; higher values mean a worse outcome); self-efficacy (SELB; min-max=0-20; higher values mean a better outcome); activity and participation (A&amp;P; min-max=0-24; higher values mean a better outcome); social support (SOZU; min-max = 0-16; higher values mean a better outcome); social stress (SOZB, min-max=0-16; higher values mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in psychosocial health scores as assessed by Health-49 at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>Health-49 = Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis by Rabung et al. (2009); subscales: somatoform complaints (SOM; min-max values=0-28; higher scores mean aworse outcome); depressiveness (DEP; min-max=0-24, higher values mean a worse outcome); phobic anxiety (PHO; min-max=0-20; higher values mean a worse outcome); psychological and somatoform complaints (PSB; min-max=0-72; higher values mean a worse outcome); psychological wellbeing (WOHL; min-max=0-20; higher values mean a better outcome); interactional problems (INT; min-max=0-28; higher values mean a worse outcome); self-efficacy (SELB; min-max=0-20; higher values mean a better outcome); activity and participation (A&amp;P; min-max=0-24; higher values mean a better outcome); social support (SOZU; min-max = 0-16; higher values mean a better outcome); social stress (SOZB, min-max=0-16; higher values mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in psychosocial health scores as assessed by Health-49 at twelve months</measure>
    <time_frame>twelve months after allocation</time_frame>
    <description>Health-49 = Hamburger Module zur Erfassung allgemeiner Aspekte psychosozialer Gesundheit für die therapeutische Praxis by Rabung et al. (2009); subscales: somatoform complaints (SOM; min-max values=0-28; higher scores mean aworse outcome); depressiveness (DEP; min-max=0-24, higher values mean a worse outcome); phobic anxiety (PHO; min-max=0-20; higher values mean a worse outcome); psychological and somatoform complaints (PSB; min-max=0-72; higher values mean a worse outcome); psychological wellbeing (WOHL; min-max=0-20; higher values mean a better outcome); interactional problems (INT; min-max=0-28; higher values mean a worse outcome); self-efficacy (SELB; min-max=0-20; higher values mean a better outcome); activity and participation (A&amp;P; min-max=0-24; higher values mean a better outcome); social support (SOZU; min-max = 0-16; higher values mean a better outcome); social stress (SOZB, min-max=0-16; higher values mean a worse outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>means in recovery support scores as assessed by Brief INSPIRE at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>Brief INSPIRE is a short version of INSPIRE by Williams et al. (2015); minimum value = 0; maximum value = 100; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>means in recovery support scores as assessed by Brief INSPIRE at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>Brief INSPIRE is a short version of INSPIRE by Williams et al. (2015); minimum value = 0; maximum value = 100; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in internalized stigma scores as assessed by SSMIS-FS application scale at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>SSMIS-SF = Self-Stigma of Mental Illness Scale - Short Form by Corrigan et al. (2012); subscale: application to self; German Version: Rüsch &amp; Brück (unpublished); minimum value = 5; maximum value = 45; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in internalized stigma scores as assessed by SSMIS-FS application at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>SSMIS-SF = Self-Stigma of Mental Illness Scale - Short Form by Corrigan et al. (2012); subscale: application to self; German Version: Rüsch &amp; Brück (unpublished); minimum value = 5; maximum value = 45; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in internalized stigma scores as assessed by SSMIS-FS application scale at twelve months</measure>
    <time_frame>twelve months after allocation</time_frame>
    <description>SSMIS-SF = Self-Stigma of Mental Illness Scale - Short Form by Corrigan et al. (2012); subscale: application to self; German Version: Rüsch &amp; Brück (unpublished); minimum value = 5; maximum value = 45; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in stigma resistance scores as assessed by ISMI at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>ISMI = Internalized Stigma of Mental Illness Inventory by Sibitz et al. (2013); subscale stigma resistance; minimum value: 5; maximum value = 20; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in stigma resistance scores as assessed by ISMI at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>ISMI = Internalized Stigma of Mental Illness Inventory by Sibitz et al. (2013); subscale stigma resistance; minimum value: 5; maximum value = 20; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in stigma resistance scores as assessed by ISMI at twelve months</measure>
    <time_frame>twelve months after allocation</time_frame>
    <description>ISMI = Internalized Stigma of Mental Illness Inventory by Sibitz et al. (2013); subscale stigma resistance; minimum value: 5; maximum value = 20; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>means in service satisfaction scores as assessed by ZUF-8 at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>ZUF-8 = Fragebogen zur Messung der Patientenzufriedenheit by Schmidt et al. (1989); minimum value = 8; maximum value = 32; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>means in service satisfaction scores as assessed by ZUF-8 at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>ZUF-8 = Fragebogen zur Messung der Patientenzufriedenheit by Schmidt et al. (1989); minimum value = 8; maximum value = 32; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in disease severity scores ay assessed by CGI at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>CGI = clinical global impressions, see Forkmann et al., 2011; minimun value = 1; maximum value = 7; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in disease severity scores ay assessed by CGI at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>CGI = clinical global impressions, see Forkmann et al., 2011; minimun value = 1; maximum value = 7; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in disease severity scores ay assessed by CGI at twelve months</measure>
    <time_frame>twelve months after allocation</time_frame>
    <description>CGI = clinical global impressions, see Forkmann et al., 2011; minimun value = 1; maximum value = 7; higher scores mean a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in general functioning scores as assessed by GAF at two months</measure>
    <time_frame>two months after allocation</time_frame>
    <description>GAF = Global Assessment of Functioning by Jones et al. (1995), minimum value = 0; maximum value = 100; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in general functioning scores as assessed by GAF at six months</measure>
    <time_frame>six months after allocation</time_frame>
    <description>GAF = Global Assessment of Functioning by Jones et al. (1995), minimum value = 0; maximum value = 100; higher scores mean a better outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in general functioning scores as assessed by GAF at twelve months</measure>
    <time_frame>twelve months after allocation</time_frame>
    <description>GAF = Global Assessment of Functioning by Jones et al. (1995), minimum value = 0; maximum value = 100; higher scores mean a better outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Severe Mental Health Condition With Indication of Hospital Admission</condition>
  <arm_group>
    <arm_group_label>Home Treatment with Peer Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive a peer supported home treatment, i.e. treatment by a home treatment/crisis resolution team with a peer support worker.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Home Treatment without Peer Support</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive conventional home treatment by a homehome treatment/crisis resolution team without contacts to a peer support worker.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Home Treatment with Peer Support</intervention_name>
    <description>After allocation participants receive a combination of Home Treatment by a multiprofessional team and Peer Support.</description>
    <arm_group_label>Home Treatment with Peer Support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Home Treatment without Peer Support</intervention_name>
    <description>After allocation participants receive professional-led Home Treatment by a multiprofessional team without Peer Support (treatment as usual).</description>
    <arm_group_label>Home Treatment without Peer Support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe mental illness with indication of hospital admission (F2, F3, F6, F41, F42)

        Exclusion Criteria:

          -  primary diagnosis of F0 or F1 (Mental disorders due to known physiological conditions;
             Mental and behavioral disorders due to psychoactive substance use)

          -  acute suicidality

          -  verbal or cognitive impairment severe enough to be unable to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Candelaria Mahlke, Dr. phil</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Candelaria Mahlke, Dr. phil.</last_name>
    <phone>0049-(0)40-7410-58933</phone>
    <email>c.mahlke@uke.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Vivantes Klinikum am Urban</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zentrum für Psychosoziale Medizin, Gesundheit Nord, Klinikverbund Bremen</name>
      <address>
        <city>Bremen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bezirkskrankenhaus Donauwörth, Fachklinik für Psychiatrie, Psychotherapie und Psychosomatik an der Donau-Ries Klinik</name>
      <address>
        <city>Donauwörth</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung für Psychiatrie, Psychosomatik und Psychotherapie, Johanniter-Krankenhaus Geesthacht</name>
      <address>
        <city>Geesthacht</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie und Psychotherapie II, Günzburg, Universitätsklinikum Ulm</name>
      <address>
        <city>Günzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Psychiatrische Klinik Lüneburg</name>
      <address>
        <city>Lüneburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abteilung für Psychiatrie, Psychotherapie und Psychosomatik, Medizinische Hochschule Brandenburg, Immanuel Klinik Rüdersdorf</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Jones SH, Thornicroft G, Coffey M, Dunn G. A brief mental health outcome scale-reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry. 1995 May;166(5):654-9.</citation>
    <PMID>7620753</PMID>
  </reference>
  <reference>
    <citation>Forkmann T, Scherer A, Boecker M, Pawelzik M, Jostes R, Gauggel S. The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome. BMC Psychiatry. 2011 May 14;11:83. doi: 10.1186/1471-244X-11-83.</citation>
    <PMID>21569566</PMID>
  </reference>
  <reference>
    <citation>Schwarzer, R. &amp; Jerusalem, M. (Hrsg.) (1999). Skalen zur Erfassung von Lehrer- und Schülermerkmalen. Dokumentation der psychometrischen Verfahren im Rahmen der Wissenschaftlichen Begleitung des Modellversuchs Selbstwirksame Schulen. Berlin: Freie Universität Berlin.</citation>
  </reference>
  <reference>
    <citation>Corrigan PW, Michaels PJ, Vega E, Gause M, Watson AC, Rüsch N. Self-stigma of mental illness scale--short form: reliability and validity. Psychiatry Res. 2012 Aug 30;199(1):65-9. doi: 10.1016/j.psychres.2012.04.009. Epub 2012 May 10.</citation>
    <PMID>22578819</PMID>
  </reference>
  <reference>
    <citation>Sibitz I, Friedrich ME, Unger A, Bachmann A, Benesch T, Amering M. [Internalized Stigma of Schizophrenia: Validation of the German Version of the Internalized Stigma of Mental Illness-Scale (ISMI)]. Psychiatr Prax. 2013 Mar;40(2):83-91. doi: 10.1055/s-0032-1332878. Epub 2013 Jan 25. German.</citation>
    <PMID>23354628</PMID>
  </reference>
  <reference>
    <citation>Rabung S, Harfst T, Kawski S, Koch U, Wittchen HU, Schulz H. [Psychometric analysis of a short form of the &quot;Hamburg Modules for the Assessment of Psychosocial Health&quot; (HEALTH-49)]. Z Psychosom Med Psychother. 2009;55(2):162-79. German.</citation>
    <PMID>19402020</PMID>
  </reference>
  <reference>
    <citation>Williams J, Leamy M, Bird V, Le Boutillier C, Norton S, Pesola F, Slade M. Development and evaluation of the INSPIRE measure of staff support for personal recovery. Soc Psychiatry Psychiatr Epidemiol. 2015 May;50(5):777-86. doi: 10.1007/s00127-014-0983-0. Epub 2014 Nov 20.</citation>
    <PMID>25409867</PMID>
  </reference>
  <reference>
    <citation>Schmidt J, Lamprecht F, Wittmann WW. [Satisfaction with inpatient management. Development of a questionnaire and initial validity studies]. Psychother Psychosom Med Psychol. 1989 Jul;39(7):248-55. German.</citation>
    <PMID>2762479</PMID>
  </reference>
  <reference>
    <citation>Gühne U, Weinmann S, Becker T, Riedel-Heller SG. [The S3 Guidelines Psychosocial Therapies in Severe Mental Illness - The Update]. Psychiatr Prax. 2018 Apr;45(3):119-121. doi: 10.1055/a-0574-4008. Epub 2018 Apr 4. German.</citation>
    <PMID>29618140</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Candelaria I. Mahlke</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

